Institute News
Most Popular
Neurotech Receives Priority Review of Biologics License Application for NT-501 as a Treatment for Macular Telangiectasia Type 2
June 20, 2024 LMRI would like to share the news that Neurotech has received Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a treatment for MacTel. For more information, please refer to the Neurotech...
What To Expect in a MacTel Imaging Exam
April 29, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. This post will explain some (but not all) of the imaging exams that your eye doctor may perform during a screening or follow up...
Results of NT-501 Phase 2 Study Published
January 16, 2019, Cumberland, RI and La Jolla, CA. The results of the NT-501 Phase 2 study sponsored by Neurotech Pharmaceuticals, Inc. (Neurotech) in collaboration with the Lowy Medical Research Institute (LMRI), have been published in the journal o...
Lowy Medical Research Institute scientists find cause of debilitating eye disease
15-year effort points to treatments to help MacTel patients and offers potential new insights into other eye diseases LA JOLLA, CA–September 11, 2019– Scientists at the Lowy Medical Research Institute (LMRI) have discovered one cause of a progre...